Demyelinating diseases articles from across Nature Portfolio

Yoshioka, Taniguchi, Homma et al. study the effect of AAV-delivered Cas9 and specific guide RNAs to correct the PMP22 gene duplication that causes Charcot-Marie-Tooth disease type 1A. They measured the effect of Cas9 editing in iPSC cells on PMP22 expression and demonstrated how editing reduces cell death and myelination defects in edited iPSC-derived Schwann cells.

Patients with autoimmune diseases require immunosuppressive treatments that affect their responses to infection and vaccination. Here, using mass cytometry, the authors to identify a role for myeloid cells in cellular and humoral responses following vaccination against SARS-CoV-2 in patients with neuroimmunological diseases.

Smouldering inflammation encompasses all non-relapsing aspects of inflammatory pathobiology in multiple sclerosis. Here, Bittner and colleagues describe the mechanisms that underlie CNS-compartmentalized smouldering inflammation and review evidence indicating that immunometabolic reprogramming driven by the CNS tissue microenvironment shapes these inflammatory responses. Potential treatments are also discussed.

Researchers in China and South Korea have developed a rapid immunodot assay to detect aquaporin 4-targeting IgG autoantibodies in the serum of individuals with neuromyelitis optica spectrum disorder.

The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and European Academy of Neurology (EAN) joint consensus statement on vaccination in people with multiple sclerosis provides highly relevant clinical guidance on immunization strategies in today’s era of effective immunotherapies. Nevertheless, several open questions remain to be addressed.

Loss of myelin integrity, which occurs during ageing, promotes deposition of amyloid-β in the brain, according to new research.